2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

T cell engager

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

1

Peptides

30

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99575
    Tarlatamab
    1 Publications Verification

    AMG-757

    		 Notch Inflammation/Immunology Cancer
    Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
    Tarlatamab
  • HY-P99033
    Mosunetuzumab
    1 Publications Verification

    BTCT-4465A; RG-7828; RO7030816

    		 CD20 CD3 Inflammation/Immunology Cancer
    Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
    Mosunetuzumab
  • HY-P991015
    Pasritamig

    JNJ-78278343; KLCB-245

    		 CD3 Cancer
    Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer .
    Pasritamig
  • HY-P990688
    Xaluritamig

    AMG-509

    		 CD3 Cancer
    Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
    Xaluritamig
  • HY-P99802
    Pasotuxizumab
    1 Publications Verification

    BAY 2010112; AMG 212; MT112

    		 CD3 Cancer
    Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
    Pasotuxizumab
  • HY-P990932
    Obrixtamig

    BI 764532; OBT 620

    		 CD3 Cancer
    Obrixtamig (BI 764532; OBT 620) is an CD3E/DLL3-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibody. Obrixtamig is a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager. Obrixtamig can be used for research of DLL3-positive small cell lung cancer .
    Obrixtamig
  • HY-P99350
    Gresonitamab
    1 Publications Verification

    AMG 910; Anti-Human CD3xClaudin18 2

    		 CD3 Cancer
    Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
    Gresonitamab
  • HY-P99948
    Etevritamab

    AMG-596

    		 EGFR CD3 Neurological Disease Cancer
    Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma .
    Etevritamab
  • HY-P99430
    Alnuctamab

    EM901; CC-93269

    		 CD3 Inflammation/Immunology Cancer
    Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Alnuctamab
  • HY-P9989
    Linvoseltamab

    REGN5458

    		 CD3 TNF Receptor Cancer
    Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) .
    Linvoseltamab
  • HY-P99798
    Pacanalotamab

    AMG 420; BI-836909

    		 CD3 Cancer
    Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
    Pacanalotamab
  • HY-P991731
    Alveltamig

    ZG006

    		 CD3 Notch Neurological Disease Cancer
    Alveltamig (ZG006) is a trispecific T cell engager targeting Delta-like ligand 3 (DLL3)/CD3, mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the researches of small cell lung cancer and neuroendocrine carcinoma .
    Alveltamig
  • HY-P990980
    Cizutamig

    CND-106; EMB-06

    		 CD3 Inflammation/Immunology Cancer
    Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and CD3. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus .
    Cizutamig
  • HY-P990981
    Clesitamig

    ALPS-12; RG-6524; RO 7616789

    		 CD3 Inflammation/Immunology Cancer
    Clesitamig (ALPS-12) is a trispecific T cell engager with two CD3/CD137 dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC) .
    Clesitamig
  • HY-P99910
    Eluvixtamab

    AMG-330

    		 CD3 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Eluvixtamab (AMG-330) is a bispecific T-cell engager. Eluvixtamab binds to CD33 and CD3 on T cells, thereby promoting T cell-mediated cytotoxicity against CD33+ cells. Eluvixtamab can be used in the research of tumors such as relapsed/refractory acute myeloid leukemia .
    Eluvixtamab
  • HY-P991526
    M701

    		CD3 Cancer
    M701 is a T-cell engager bispecific humanized antibody targeting epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). M701 binds to EpCAM on tumor cells and CD3 on T cells, thereby linking the two cell populations to achieve targeted cytotoxicity and T cell-mediated cytotoxicity. M701 is applicable to research related to advanced epithelial solid tumors .
    M701
  • HY-P990104
    Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)

    		Notch Inflammation/Immunology Cancer
    Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.
    Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)
  • HY-P99523
    Vepsitamab

    AMG 199

    		 CD3 Cancer
    Vepsitamab (AMG 199) is a bispecific T-cell engager (HLE BiTE) that binds to MUC17 and CD3. Vepsitamab directs CD3-positive cells to target MUC17-positive cells. Vepsitamab induces cell activation and proliferation. Vepsitamab is applicable to research related to gastric cancer and gastroesophageal junction (g/gej) cancer .
    Vepsitamab
  • HY-P990785
    Etentamig

    ABBV-383; TNB 383B

    		 CD3 Cardiovascular Disease Inflammation/Immunology Cancer
    Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
    Etentamig
  • HY-P990710
    Acimtamig

    AFM13

    		 TNF Receptor Cancer
    Acimtamig (AFM13) is a CD30/CD16A bispecific innate cell engager. Acimtamig binds to the CD16A expressed on natural killer (NK) cells and binds to CD30 on CD30-expressing tumor cells, thereby selectively cross-linking tumor and NK cells. Acimtamig can be used for the study of eripheral T-cell lymphoma (PTCL) .
    Acimtamig
  • HY-P99757
    Nivatrotamab

    Hu3F8-BsAb

    		 CD2 CD3 Cancer
    Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .
    Nivatrotamab
  • HY-P99814
    Pavurutamab

    AMG-701

    		 CD3 Inflammation/Immunology Cancer
    Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
    Pavurutamab
  • HY-P99916
    Emirodatamab

    AMG-427

    		 FLT3 CD3 TNF Receptor Inflammation/Immunology Cancer
    Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .
    Emirodatamab
  • HY-P99914
    Emfizatamab

    GNC-038

    		 PD-1/PD-L1 CD19 TNF Receptor CD3 Interleukin Related IFNAR Inflammation/Immunology Cancer
    Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .
    Emfizatamab
  • HY-P990730
    Cabotamig

    ARB202

    		 CD3 Cadherin Cancer
    Cabotamig is a humanized bispecific T-cell engager antibody targeting CDH17/CD3. Cabotamig is generated from anti-CDH17 monoclonal ARB102 by linking a CD3-binding scFv in the format of IgG4-scFv. Cabotamig can be used for the research of cancer, such as gastric cancer and colon cancers .
    Cabotamig
  • HY-P991479
    Amtabafusp alfa

    GS-8588

    		 HIV CD3 Infection
    Amtabafusp alfa (GS-8588) is an envelope-targeting bispecific T-cell engager for HIV treatment. Amtabafusp alfa redirects effector T cells by binding to CD3 via a humanized anti-CD3 Fab domain and to HIV envelope proteins via an engineered CD4 domain 1 variant. Amtabafusp alfa exhibits potent, broad-spectrum activity against a variety of HIV isolates and specifically kills HIV-infected cells. Amtabafusp alfa can be used for research on HIV infection .
    Amtabafusp alfa
  • HY-P992370
    HPN601

    		Interleukin Related IFNAR Cancer
    HPN601 is a protease-activated EpCAM-targeting T-cell engager that binds EpCAM competitively and induces T-cell mediated tumor cell killing. HPN601 binds to EpCAM, CD3e and albumin; albumin binding extends its half-life, while masking groups keep the molecule inert outside the tumor microenvironment. HPN601 significantly reduces the release levels of IFN-γ, IL-2, IL-6 and IL-10. HPN601 can be used in research related to cancers such as breast cancer and gastric cancer .
    HPN601
  • HY-P11280A
    PRAME peptide (425-433) acetate

    		Melanocortin Receptor Cancer
    PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .
    PRAME peptide (425-433) acetate
  • HY-P992390
    IOR-T3

    		CD3 Inflammation/Immunology
    IOR-T3 is a monoclonal antibody targeting CD3, with biological activities related to T cell activation regulation . IOR-T3 uses its variable region to competitively engage surface CD3 on lymphocytes and trigger robust T cell proliferation and activation. IOR-T3 and its derivatives can be used in studies related to acute transplant rejection .
    IOR-T3
  • HY-P992457
    SAR444200

    		Glycoprotein VI Interleukin Related Cancer
    SAR444200 is a nanobody T-cell engager targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). SAR444200 has a KD of 0.023 nM for human GPC3 and a KD of 5.2 nM for human TCRαβ. SAR444200 mediates T-cell-dependent cytotoxicity, with high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used for the research of GPC3 + solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma .
    SAR444200
  • HY-P992341
    D8P1C1

    		MMP Cancer
    D8P1C1 is a high-affinity ADAM17 inhibitor (with a Kd of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. 89Zr-DFO-D8P1C1 radioimmunological PET imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer .
    D8P1C1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: